A number of drugs developed against cancer-specific molecular targets have been shown to offer survival benefits alone or in combination with standard treatments, especially for those cases in which tumor pathogenesis is dominated by a single molecular abnormality. One example for such a tumor type is alveolar rhabdomyosarcoma (aRMS), which is characterized by a specific translocation creating the oncogenic PAX3/FKHR transcription factor, believed to be the molecular basis of the disease. Recently, we were able to show that the small molecule inhibitor PKC412 (midostaurin) shows strong antitumor activity against aRMS by reducing the transcriptional activity of PAX3/FKHR. In this study, we screened for combination strategies that are superior to PKC412-only treatment and found that the combination of PKC412 with histone deacetylase inhibitors like valproic acid (VPA) synergistically induced apoptosis resulting in suppressed aRMS tumor growth in vivo. We provide evidence that the antitumor effect on combination treatment is achieved by VPA-induced reactivation of p21, which is downregulated in aRMS cells by destabilization of the transcriptional regulator EGR1 by PAX3/FKHR. Our study highlights a possible mechanism behind the increased efficacy and indicates that different arms of PAX3/FKHR oncogenicity can be exploited therapeutically by the specific combination of drugs to increase their therapeutic potential.
Introduction
The phenomenon of oncogene addiction allows the development of targeted therapies for poor-outcome malignancies whereby the clinical success of kinase inhibitors such as imatinib shows the feasibility of such an approach. However, clinical experience also indicates that the risk of outgrowth of therapy-resistant subclones with single-agent treatments is rather high and their efficacy can be very limited. Hence, and given the vast number of agents in pre-clinical development, one of the big challenges ahead will be to define rational combination treatments that show the most promising clinical benefit. Such combinations might be directed against one signaling pathway at different molecular levels or target complementary pathways to achieve maximal efficacy.
As a model to examine such possibilities we use the pediatric sarcoma rhabdomyosarcoma (RMS). RMS is the most common pediatric soft tissue cancer and accounts for approximately 5-8% of all malignancies in children (Merlino and Helman, 1999) . Histopathologically, two main subtypes of RMS, embryonal RMS and alveolar RMS (aRMS) can be distinguished. Although embryonal RMS has a favorable prognosis with survival rates of up to 94% for the most favorable subgroups, the aRMS histotype is associated with poor survival rates of 30% only as aRMS occurs at unfavorable sites and shows a highly malignant phenotype (Meyer and Spunt, 2004) . Also within the stratified patient cohort of metastatic RMS with two or fewer metastatic sites, non-embryonal histology is associated with an unfavorable prognosis while embryonal histology contributes significantly to better prognosis, with 21 and 40% of failure-free survival, respectively (Breneman et al., 2003) . Dose intensification and the use of multiagent chemotherapy offer only very modest survival benefits for children with disseminated or recurrent disease and unfavorable RMS histology (Pappo et al., 1999; Smith et al., 2001) . Therefore, new therapeutic strategies are urgently needed for such high-risk patients.
The majority of aRMS cases is associated with the chromosomal translocation t(2;13) generating the PAX3/FKHR fusion protein. This chimeric transcription factor contains the two DNA-binding domains of PAX3 and the transactivation domain derived from FKHR, also known as FOXO1A. As PAX3/FKHR is a stronger transactivator than its wild-type counterpart, it has been suggested that the oncogenic potential of the fusion results from dysregulation of PAX3 target genes. Established aRMS tumors are dependent on continuous expression of PAX3/FKHR similar to multiple examples of cancers that show to be addicted to certain activated oncogenes. Hence, these tumor-specific oncogenic transcription factors represent an ideal therapeutic target for the development of novel therapeutic strategies.
Along these lines, we recently reported that the kinase inhibitor PKC412 (midostaurin) can influence the oncogenic activity of PAX3/FKHR through modulation of specific phosphorylation sites within the PAX3 domain (Amstutz et al., 2008) . Phosphorylation at these sites was shown to perturb efficient DNA-binding. Consequently, treatment of aRMS with PKC412 resulted in potent antitumoral effects both in vitro as well as in vivo.
Apart from this well-investigated oncogenic activity at the level of direct target gene activation, PAX3/FKHR also exerts a repressive effect that has been less well characterized. Recently, it has been reported that PAX3/ FKHR has a protein-destabilizing effect (Roeb et al., 2007) , as PAX3/FKHR was shown to directly interact with the early growth responsive transcription factor EGR1 thereby targeting EGR1 for proteasomal degradation. EGR1 has important roles in regulating cell growth, differentiation and development (Liu et al., 1996) and has been shown to mediate expression of p57Kip2 as one of its target genes (Roeb et al., 2007) .
In this study, we show that degradation of EGR1 by PAX3/FKHR leads to the repression of the tumor suppressor and cell cycle regulator p21 and thereby identify p21 as a novel gene that is repressed by PAX3/ FKHR.
In an attempt to find substances synergistic with PKC412 in their ability to inhibit aRMS cell proliferation, we found that reactivation of p21 expression by histone deacetylase (HDAC) inhibitors strongly augments PKC412-mediated apoptosis in aRMS cells, in vitro and in vivo. These findings highlight the complexity of aRMS tumor pathogenesis created by the translocation-positive genotype and provide the basis for an evidence-based combination treatment of aRMS with PKC412 and HDAC inhibitors to exert a therapeutic benefit by targeting different arms of PAX3/FKHR oncogenicity.
Results
Combination of PKC412 with valproic acid (VPA) leads to synergistic antitumor activity on aRMS cells in vitro through reactivation of p21 expression levels We recently identified PKC412 as a potent antitumorigenic agent for aRMS treatment in vitro and in vivo (Amstutz et al., 2008) . To further increase treatment efficacy, we performed in vitro combination studies with chemotherapeutic agents used in RMS therapy or HDAC inhibitors, which have been shown to act synergistically with PKC412 against acute myelogenous leukemia (Bali et al., 2004) . IC 50 values of these agents were determined in aRMS cell lines RH4 and RH30 either as single agents or in combination with 50 nM PKC412, a concentration that is approximately 10 times below its IC 50 and thus only has a marginal influence on cell viability by itself. To evaluate synergistic effects, a combination index was calculated, which is the IC 50 ratio between combined and single treatments and which indicates synergism at a value o1 (Figure 1a) . Strong synergistic effects with combination index values of 0.48 and 0.61 were observed in RH4 cells for both HDAC inhibitors, VPA and SAHA, whereas from the chemotherapeutic compounds only vincistrine showed weak synergism in combination with PKC412. In RH30 cells, all compounds tested showed some synergistic effects with PKC412. Similar to RH4 cells, the lowest combination index value could be detected on cotreatment with VPA ( Figure 1a) . These results suggest a rationale for combining PKC412 and HDAC inhibitors, especially VPA, and prompted us to further analyze this combination for treatment of aRMS.
To confirm VPA as a combination partner for PKC412, we next determined whether cotreatment with clinical applicable concentrations of VPA would sensitize aRMS cells to cell death induced with IC 50 concentrations of PKC412. As expected, single treatment with 0.5 mM PKC412 resulted in a strong induction of cell death for both aRMS cell lines. By itself, VPA exerted no cytotoxicity after 72 h of continuous exposure to 1 mM. However, cotreatment with 1 mM VPA dramatically enhanced PKC412-induced cell death, indicating synergistic antitumoral activity on aRMS cells (Figure 1b) .
As PKC412-induced cell death is due to caspase-3-dependent apoptosis (Amstutz et al., 2008) , we tested whether VPA might further enhance apoptosis by an activated caspase-3 assay. This revealed an at least twofold increase in the number of apoptotic cells in combined treatment compared with PKC412 single treatment (Figures 2a and b) . RH4 cells showed an increased apoptotic response compared with RH30 cells, with values of 50.8 and 42.5%, respectively, consistent with the observed stronger induction of cell death for these cells.
To further confirm these findings, we monitored PARP cleavage in cells treated with drugs from 2 to 16 h by western blot analysis. In both aRMS cell lines, time-dependent increase in PARP cleavage was more pronounced after combination treatment compared with either single treatment alone (Figure 2c ). In addition to VPA, we observed that also other HDAC inhibitors like sodium butyrate or SAHA (Figures 1a, b and data not shown) can act in combination with PKC412 to mediate an enhanced reduction of aRMS cell viability. Taken together, these results clearly show that HDAC inhibitors synergize with PKC412 to enhance apoptosis in aRMS cells. As different HDAC inhibitors have a similar synergistic effect, their mode of action is likely to rely on a class-specific mechanism.
One very prominent effect observed for a large panel of HDAC inhibitors is induction of p21 (Sowa et al., 1997; Archer et al., 1998; Kim et al., 2001; Wilson et al., 2006) . Hence, we determined p21 expression levels on HDAC inhibitor treatment alone and in combination with PKC412. p21 protein levels were significantly upregulated on HDAC inhibitor treatment irrespective of additional treatment with PKC412 ( Figure 2d and Supplementary Figure S1a ). This is true for both aRMS cell lines RH4 and RH30, which show similar levels of PAX3/FKHR expression (Supplementary Figure S1b) and are either deleted in p53 or carry p53 mutations (Barlow et al., 2006) , thereby excluding a role of p53 in p21 promoter activation.
These observations suggest that the synergistic antitumoral effects of the combination might result from upregulation of the well-established HDAC inhibitor target p21. To verify the functional significance of p21 induction for enhanced apoptotic response, we prevented p21 accumulation using RNA interference and compared the level of apoptosis on VPA/PKC412 exposure to control small interfering RNA (siRNA)-treated cells. As shown in Figure 2d , the extent of PARP cleavage on combination treatment increased to a ratio of 0.4 compared with 0.3 observed for PKC412-only treatment. In p21-depleted cells, this ratio remained unchanged at 0.3 indicating that p21 depletion prevents VPA from enhancing PKC412-induced apoptosis (P ¼ 0.0133). Collectively, these data suggest that induction of p21 by VPA is an important component contributing to enhanced apoptosis on cotreatment with PKC412.
PAX3/FKHR mediates repression of p21
As a number of oncogenes repress p21 to promote tumorigenesis (as reviewed in Gartel and Radhakrishnan (2005) ), we sought to determine whether also the PAX3/ FKHR oncogene exerts a suppressive effect on p21 expression. Hence, we silenced endogenous PAX3/FKHR in aRMS cells and measured p21 protein levels. As shown in Figure 3a and Supplementary Figure S2 , reduced PAX3/FKHR levels led to dramatic increase in p21 protein expression in a panel of aRMS cell lines.
To further validate PAX3/FKHR as a negative regulator of p21 expression, we examined its effect directly on the p21 promoter by luciferase reporter assays. Transfection of 293T cells with a PAX3/FKHR vector decreased p21 promoter driven luciferase expression to 26% ( Figure 3b ).
As PAX3/FKHR interferes with expression of p21 and aRMS cells undergo apoptosis on silencing of PAX3/FKHR by oligonucleotides (Bernasconi et al., 1996) or siRNA (Ebauer et al., 2007) , we assessed the relevance of p21 induction for this apoptotic response by co-transfecting RH4 cells with siRNAs against p21 and PAX3/FKHR. Compared with control or p21 siRNA-transfected cells, which only show ratios of cleaved to uncleaved PARP of 0.1 and 0.07, respectively, PAX3/FKHR siRNA-transfected cells show strongly enhanced PARP cleavage (0.43). Importantly, this apoptotic response to PAX3/FKHR silencing was rescued upon co-depletion of p21 as indicated by a reduction of PARP cleavage ratio to 0.18 ( Figure 3c ). These results show that PAX3/FKHR represses p21 levels and suggest that upregulation of p21 in response to PAX3/FKHR interference is necessary for efficient induction of apoptosis.
PAX3/FKHR controls expression of p21 through EGR1
As inhibition of DNA-binding of PAX3/FKHR by PKC412 (Amstutz et al., 2008) was not able to induce p21 expression (Figure 2d ), we reasoned that PAX3/ FKHR might regulate p21 gene expression at levels other than transcription. Recently, it has been shown that PAX3/FKHR can interact with and mediate destabilization of the transcription factor EGR1 ( (Roeb et al., 2007) and Supplementary Figures S3a and b ) which itself can directly modulate gene expression of p21 ((Ragione et al., 2003; Choi et al., 2008) and Supplementary Figure S3c ). These findings suggest that repression of p21 by PAX3/FKHR might be mediated by degradation of the transcription factor EGR1.
To address this hypothesis, we first examined the expression levels of p21 and EGR1 in control human myoblasts and a series of aRMS tumor cell lines by immunoblot analysis. These experiments revealed a significant decrease in both p21 and EGR1 protein expression levels in aRMS cell lines in comparison with control myoblasts (Figure 4a) .
Proteasome inhibition by MG132 prevents EGR1 destabilization by exogenous PAX3/FKHR in 293T cells ((Roeb et al., 2007) and Supplementary Figure  S3b. ) Therefore, we treated aRMS cells with MG132. This caused a dose-dependent increase both of EGR1 and p21 protein levels ( Figure 4b ). As p21 itself is subject to ubiquitination, this increase most likely results from increased p21 protein stability rather than elevated transcription levels induced by EGR1. To analyze the relevance of EGR1 destabilization by PAX3/FKHR on p21 transcription, we performed luciferase reporter assays using a p21 promoter deletion construct lacking the distal p53 consensus-binding site.
As shown in Figure 4c in 293T cells, p21 promoter activity increased with the amount of transfected EGR1, suggesting that EGR1 can induce p21 transcription independent of p53. Moreover, co-expression of PAX3/ FKHR inhibits EGR1 activation of the p21 promoter in a dose-dependent manner. Interestingly, this inhibition could be partially rescued by treatment with increasing amounts of MG132 (Figure 4d and Supplementary Figure S3b ). This suggests that p21 protein levels are controlled in aRMS cells through transcriptional activation by EGR1 that itself is destabilized by PAX3/FKHR.
To further validate this hypothesis, we assessed whether silencing of EGR1 influences p21 expression levels. As shown in Figure 4a , untreated RH4 cells express only low levels of endogenous EGR1 protein. Moreover, further depletion by RNA interference mediated yet a reduction of p21 expression, which was proportional to EGR1 knockdown efficiency (Figure 4e and Supplementary Figure S3d) . In addition, silencing of PAX3/FKHR mediated an increase in EGR1 as well as p21 protein levels. These data are consistent with the notion that EGR1 regulates p21 transcription and that on knockdown of PAX3/FKHR, EGR1 is no longer subject to proteasomal degradation and hence able to transcriptionally activate p21.
PKC412/VPA combination treatment results in reactivation of p21 expression levels and enhanced antitumoral action in vivo To analyze the value of combination therapy in vivo, we used an aRMS xenograft mouse model generated by subcutaneous injection of RH4 cells into immunocompromised (nu/nu) mice. As shown in Figure 5a , daily administration of VPA (400 mg/kg) or PKC412 (100 mg/kg) alone for a 7-day time period was able to reduce tumor growth by approximately 50%. Interestingly, combination treatment reduced tumor growth by a further three-to fourfold compared with either single treatment alone.
In line with our in vitro results, immunohistochemical analysis of tumor sections revealed that VPA treatment alone or in combination with PKC412 led to elevated levels of p21 protein in vivo (Figure 5b ). In addition, analysis of tumors subjected to each single treatment showed that VPA had only a minimal effect on proliferation whereas PKC412 treatment caused a 25% reduction in the number of proliferative cells (Figure 5c ). Both single treatments also led to a twofold increase in the number of apoptotic cells compared with placebo-treated tumors (Figure 5d ). Importantly, however, combination therapy resulted in both strongest decrease in proliferation (by 40%) and highest number of apoptotic cells (72 cells per visual field) compared with placebo treatment (11 cells per visual field) (Figures 5c and d) . In summary, these results suggest that also in vivo reactivation of p21 contributes to augment PKC412-mediated antitumorigenic activity and therefore highlight PKC412/VPA combination treatment as an evidence-based novel treatment strategy for aRMS. Discussion aRMS represents a therapeutic challenge because of its frequent resistance to conventional chemotherapy. Especially relapsed aRMS patients have a very poor prognosis (Pappo et al., 1999; Raney et al., 2001) . Therefore, the development of novel treatment modalities is necessary to improve the clinical outcome for aRMS patients.Recently, we identified the kinase inhibitor PKC412 to exert a potent antitumor effect in aRMS in vitro and in vivo by reducing the transcriptional activity of the PAX3/FKHR oncogene (Amstutz et al., 2008) . However, to minimize the potential development of resistance and further improve efficacy the use of drug combinations is a well-established pharmaceutical principle. As numerous novel agents are now being developed for clinical testing, this creates almost limitless possibilities of combination regimens. Therefore, development of strategies to identify the most promising combinations will become very important. 
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In this study, we show that the HDAC inhibitor VPA, a well-established drug used in therapy for seizures and bipolar disorders, acts as a potent combination partner for PKC412 to mediate increased induction of apoptosis in aRMS cells, both in vitro and in vivo. Interestingly, combinations with standard cytotoxic drugs used in RMS treatment showed only minimal synergistic effects. This is in contrast to acute myeloid leukemia for which PKC412 is currently evaluated in phase II clinical trials, as combinations with conventional antileukemic agents show superior anticancer activity for FLT3 mutationpositive acute myelogenous leukemia compared with single treatment alone (Furukawa et al., 2007) . Only one study in acute myelogenous leukemia suggested that HDAC inhibitors could be used effectively in combination with PKC412 (Bali et al., 2004) .
In vivo, further reduction in tumor growth by the combination was observed after a short treatment period of only 7 days. It will be interesting to evaluate this combination in respect to other targeted drugs that have been suggested as novel drugs for therapy of RMS, such as, for example, agents inhibiting the IGF-1R pathway (Cao et al., 2008; Kolb et al., 2008) .
We provide evidence that VPA exerts its synergistic anticancerous activity on aRMS cells by mediating reactivation of p21 expression levels, again both in vitro and in vivo. Interestingly, this effect could also be observed with other HDAC inhibitors and was not restricted to VPA. Epigenetic repression of p21 has recently been shown to occur through HDAC4-mediated reduced acetylation of Sp1/Sp3-binding sites at the proximal promoter of p21 in a human glioblastoma model (Mottet et al., 2009) . This effect was shown to be p53-independent, which is similar to the results obtained here because aRMS cell lines used in this study are either depleted or mutated in p53 (Barlow et al., 2006) and the p21 reporter construct did not include p53-binding sites. Hence, transcriptional repression of p21 might occur through HDAC4 also in the RMS model and the use of more specific HDAC4 inhibitors might further enhance the specificity of our treatment strategy.
As p21 levels in aRMS are usually low (Figures 3 and 4) , an important goal was to identify the relevant mechanisms of repression. Interestingly, we found that p21 expression is strongly upregulated on silencing of PAX3/ FKHR. In addition, efficient induction of apoptotic aRMS cell death on PAX3/FKHR depletion occurs, at least in part, through p21 because its depletion can rescue from apoptosis. Given that PAX3/FKHR can destabilize the transcription factor EGR1 (Roeb et al., 2007 (Roeb et al., , 2008 and that EGR1 itself was shown to modulate p21 transcription (Ragione et al., 2003) , we hypothesized that EGR1 is critically involved in p21 activation on PAX3/FKHR depletion. This conclusion is supported by several lines of evidence: first, EGR1 and p21 protein expression levels are reduced in a series of translocation-positive aRMS tumor cell lines as compared with human myoblasts. Second, enhanced induction of p21 reporter activity on EGR1 overexpression was strongly inhibited by co-transfection with PAX3/FKHR. Third, this inhibition could be prevented by treatment with the proteasome inhibitor MG132. Finally, silencing of endogenous PAX3/FKHR induced protein expression of both EGR1 as well as its transcriptional target p21. Hence, we identified with p21, apart from p57 (Roeb et al., 2007) , a second important target gene which is transcriptionally modulated by destabilization of EGR1 through PAX3/ FKHR, thereby also validating this newly described role of PAX3/FKHR in aRMS tumor cells (Roeb et al., 2007) . These data indicate that aRMS tumor cells exert both epigenetic regulatory strategies and destabilization of the transcription factor EGR1 as complementing mechanisms to ensure downregulation of p21, indicating a potential tumor-suppressing function for p21 also in aRMS pathology.
These data also suggest novel treatment possibilities for aRMS tumors: one rationale might be to examine the proteasome as a target of potential therapeutic value. However, as it could be shown that PAX3/FKHR rather than EGR1 is ubiquitinated (Roeb et al., 2008) , strategies that exploit proteasome inhibition might also lead to increased protein levels of transcriptional active PAX3/FKHR in aRMS tumor cells. Therefore, we suggest combination strategies of PKC412 with HDAC inhibitors such as VPA, as this cotreatment results in reactivation of the EGR1 target p21 and in reduction of the transcriptional activity of PAX3/FKHR. Thus, the molecular mechanism of this synergistic combination is most likely based on targeting both the transcriptional and protein-degradation activity of the PAX3/FKHR oncogene ( Figure 6 ). As both therapeutic agents used for the combination treatment are broad spectrum drugs, it is likely that other so far not identified mechanisms might contribute to their activity. Nevertheless, the use of HDAC isoform-specific inhibitors combined with more specific kinase inhibitors (after identification of the signaling pathway responsible for PAX3/FKHR phosphorylation) might provide additional specificity to this treatment strategy. Whether this would also translate to enhance clinical benefits, remains to be analyzed.
Altogether, our study provides novel insights into the oncogenic mechanisms of PAX3/FKHR and marks the combination of VPA and PKC412 as an evidence-based alternative to standard chemotherapy protocols for poorly prognosed aRMS patients.
Materials and methods
Cell lines and pharmacologic inhibitors aRMS cell lines RH4 and RH28 were kindly provided by Peter Houghton (St Jude Children's Hospital, Memphis, TN, USA) and RMS13 were obtained from the Ludwig-Maximilian University (Munich, Germany). RH30 as well as 293T cells were purchased from the American Type Culture collection (LGC Promochem, Molsheim Cedex, France). A33 and B6M myoblasts were established in our laboratories (Genini et al., 1996) . SkM1 and SkM2 myoblasts were purchased from Promocell (Allschwil, Switzerland). Etoposide, vincristine, carboplatin, natrium butyrate and VPA were purchased from Sigma (Buchs, Switzerland). Daunorubicine (Cerubidine) was obtained from Sanofi-Aventis (Geneva, Switzerland), topotecan from Glaxo Smith Kline (Mu¨nchenbuchsee, Switzerland) and SAHA from Alexis Biosciences (Lausen, Switzerland). PKC412 was kindly provided by Novartis (Basel, Switzerland).
In vitro combination studies IC 50 values of drugs alone or in combination with 50 nM PKC412 were determined by MTT assays (Roche, Basel, Switzerland) according to the manufacturer's protocol. In all, 10 000 cells per well of a 96-well plate were treated with increasing concentrations of daunorubicine (0-3 mM), etoposide (0-30 mM), topotecan (0-10 mM), vincristine (0-5 nM), carboplatin (0-1 mM), VPA (0-30 mM) or SAHA (0-6 mM) in a final volume of 100 ml for 96 h. For each concentration, the percent viable cells compared with control were plotted against the logarithm of drug concentrations. IC 50 values were then calculated by nonlinear regression curve fitting using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).
Trypan blue exclusion
The dye (Sigma) exclusion test was used to determine the number of viable and dead cells present in trypsinized cell suspensions on inhibitor treatment.
Caspase-3 assay Activated caspase-3 levels were detected by CaspGLOW Red Active Caspase-3 staining kit (BioVision, Amsbio, Lugano, Switzerland) according to the manufacturer's instructions. Cells were treated with inhibitors for 48 h. Active caspase-3-positive cells were determined by fluorescence microscopy. For each treatment, a minimum of 500 cells were counted.
Immunoblotting
Proteins were separated using a NuPAGE electrophoresis system (Invitrogen, Basel Switzerland). Western blots were probed using primary antibodies against poly(ADP-ribose) polymerase (PARP, 1:1000), p53 (1:1000), p21
Waf1/Cip1 (12D1, 1:1000, all from Cell Signaling Technology, Allschwil, Switzerland), EGR1 (588, sc-110, 1:500, Santa Cruz Biotechnology, Heidelberg, Germany), FKHR (C20; 1:500; Santa Cruz Biotechnology) and b-actin (A2103; 1:1000; Sigma).
siRNA-mediated silencing Cells were transfected with either PAX3/FKHR break-pointspecific siRNA (Kikuchi et al., 2008) , p21 siRNA, EGR1#1 siRNA or scrambled negative control (AllStars, Qiagen, Hombrechtikon, Switzerland) siRNA (all obtained from Qiagen, except for EGR1#2 from Ambion (Huntingdon, UK)) for 48 h Figure 6 Schematic representation of the molecular interactions described in this study. Briefly, phosphorylation regulates the transcriptional activity of PAX3/FKHR (Amstutz et al., 2008) whereas ubiquitination of PAX3/FKHR mediates codegradation of the transcription factor EGR1 (Roeb et al., 2007) thereby reducing p21 expression levels. Therefore, the combination of VPA and PK412 may provide a therapeutic benefit in the treatment of aRMS through the abrogation of different levels of PAX3/FKHR oncogenic activity.
using N-ter nanoparticle transfection reagent (Sigma-Aldrich) according to the manufacturer's instructions. For knockdown experiments in combination with PKC412/VPA treatment, cells were incubated with siRNA for 40 h and subsequently exposed to treatment for additional 8 h.
Proteasome inhibition assays RH4 cells were treated with MG132 (VWR International AG, Dietikion, Switzerland) dissolved in dimethylsulphoxide or dimethylsulphoxide alone for 3 h. For proteasome inhibition during luciferase assay experiments, 293T cells were treated with indicated concentrations of MG132 16 h before harvesting.
Transactivation assays and plasmids
The PAX3/FKHR construct together with a reporter plasmid containing the luciferase gene downstream of a p21 promoter fragment that spans nt À150 to þ 39 and lacks the p53-binding site (p21-Luc (À150/ þ 38), (Kim and Rossi, 2007) ) and a plasmid containing the lacZ gene were transfected into 293T cells. For EGR1 destabilization assays, 293T cells were in addition to these plasmids co-transfected with increasing quantities of EGR1 plasmid. Total DNA mass was kept constant by the addition of pcDNA3.1. Wherein indicated, cells were treated with MG132, followed by lysis in reporter lysis buffer (Promega, Wallisellen, Switzerland). b-Galactosidase and luciferase activities were determined with the corresponding assay systems (Promega) and luciferase activity values were normalized with the b-galactosidase activity values.
Treatment of aRMS xenograft mice
In all, 10 7 RH4 cells resuspended in 100 ml of phosphatebuffered saline, were subcutaneously injected into the right flank of female CD-1 athymic nude mice (nu/nu) (Charles River, Germany). When tumors reached a volume of approximately 125 mm 3 , mice were treated with 100 mg/kg/ day PKC412, 100 mg/kg/day PKC412 and 400 mg/kg/day VPA, 400 mg/kg/day VPA or placebo. Treatment was performed for 7 consecutive days. Tumor size was determined every 3 days by measuring two diameters (d 1 , d 2 ) in right angles using a calliper. Tumor volumes were calculated using the formula V ¼ (4/3) p r 3 (r ¼ (d 1 þ d 2 )/4). PKC412, formulated in a microemulsion (Novartis), was applied orally according to the guidelines of Novartis. VPA, dissolved in phosphate-buffered saline, was administered intraperitoneally. Every treatment group consisted of five animals.
Immunohistochemistry
For histologic analysis, three mice per treatment group were killed at the end of the in vivo experiment treatment period (day 25). Tumors were isolated, fixed in 4% paraformaldehyde in phosphate-buffered saline and paraffin-embedded. Tumor sections were subjected to stainings with rabbit-polyclonal p21 antibody using standard histological techniques. TUNEL analysis was performed according to the manufacturer 0 s instructions (Roche). Furthermore, tumor sections were stained for the proliferation marker Ki-67 by using a monoclonal rabbit Ki-67 antibody (NeoMarkers, Fremont, CA, USA) and the Ventana iView DAB Detection Kit (Ventana Medical Systems, Illkirch, France). TUNEL-or Ki-67-positive cells were counted in 12 randomly selected visual fields at Â 100 magnification (634.2 mm Â 476.5 mm).
